Merck revealed promising Phase 3 trial results for WINREVAIR, a new treatment aimed at pulmonary arterial hypertension (PAH). The HYPERION study involved about 320 global participants already ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $80.16. Confi ...

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...